CHMP pulls rank on EMA pharmacovigilance panel over Servier bone drug
This article was originally published in SRA
Executive Summary
The European Medicines Agency says that Servier's osteoporosis treatment Protelos/Osseor (strontium ranelate) should remain on the market with additional restrictions, rejecting a recommendation from its Pharmacovigilance Risk Assessment Committee that the product be suspended1-3.